 TEL AVIV, Israel, May 12, 2021 GLOBE NEWSWIRE -- InspireMD, Inc. NYSE American: NSPR, developer of the CGuardTM Embolic Prevention System EPS for the prevention of stroke caused by the treatment of Carotid Artery Disease CAD, today announced it has appointed seasoned marketing executive Kathryn Katie Arnold to its Board of Directors. With more than two decades of strategy and commercialization experience within the medical device industry, Ms. Arnold joins as the company advances global commercialization and enrollment in the U.S. IDE trial of its novel CGuard EPS technology. 